Rubedo Life Sciences, founded in 2018, is a promising player in the biotechnology, healthcare, and life sciences sectors. Headquartered in Sunnyvale, CA, this biopharmaceutical company is heralding a new era in age-related disease treatment with its pioneering approach.
The company is known for its slogan: "Medicines to keep you biologically young by targeting the pathological cells that drive chronic diseases of aging." It develops innovative therapies targeting senescent cells responsible for chronic disorders in fields such as pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Central to this innovation is Rubedo's proprietary ALEMBIC™ drug discovery platform.
Their recent $40.00M Series A funding round on 01 April 2024 was backed by prestigious investors including Khosla Ventures, Refactor Capital, Ahren Innovation Capital, and G42 Group. With a leadership team of industry veterans spanning both large pharma and biotech, Rubedo Life Sciences is poised to significantly impact the treatment of chronic age-related diseases.